肥胖和新出现心房的风险
Thomas J Wang1, Helen Parise, Daniel Levy
1Framingham Heart Study, Framingham, Mass 01702-5827, USA.
JAMA
|November 25, 2004
概括
肥胖会增加患心房动 (AF) 的风险. 这种高风险似乎是由左心房扩大引起的,这表明体重管理可能会降低AF发生率.
科学领域:
- 心脏病学 心脏病学
- 流行病学 流行病学
- 公共卫生 公共卫生
背景情况:
- 肥胖与心房扩大和腹功能障碍有关,这是已知的心房动 (AF) 预测因素.
- 肥胖和AF风险之间的直接关联仍然不清楚.
研究的目的:
- 调查身体质量指数 (BMI) 与事故AF风险之间的关系.
- 确定左心房直径是否介导肥胖和AF之间的关联.
主要方法:
- 对5282名没有基线AF的参与者进行了前性,基于社区的队列研究.
- 身体质量指数 (BMI) 分析为连续和分类变量 (正常,超重,肥胖).
- 多变量模型调整为临床混因素和心声图左心房直径.
主要成果:
- 在平均随访13.7年期间,526名参与者患有AF.
- 在男性和女性中,AF发病率与更高的BMI类别相比增加.
- 肥胖 (BMI ≥30.0) 与增加AF风险相关 (HR 1.52男性,1.46女性).
- 在调整左心脏直径后,BMI和AF风险之间的关联不再显著.
结论:
- 肥胖是一个重要的,潜在的可修改的AF风险因素.
- 左心房扩张似乎调解了与肥胖相关的AF风险增加.
- 体重管理干预措施可能有助于减少人口的AF负担.
更多相关视频
08:10Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation
Published on: July 20, 2022
08:05Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice
Published on: June 29, 2022
相关概念视频
Disturbances in Heart Rhythm
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Dysrhythmias II: Classification of Tachyarrhythmias
Tachyarrhythmias are a type of dysrhythmia where the heart rate exceeds 100 beats per minute. Here are some common types of tachyarrhythmias:Sinus TachycardiaSinus tachycardia originates from increased impulses from the sinus node, leading to an elevated heart rate. It is often triggered by stress, fever, or exercise.Patients may experience palpitations, a sensation of a racing heart, dizziness, and chest discomfort.Causes and Risk Factors: Common causes include physical exertion, emotional...
Dysrhythmias VI: Management of Dysrhythmias
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
